This underscores MCT1 as a promising target for tumor therapy, as its inhibition not only eliminates hypoxic tumor cells but also allows for the treatment of more vulnerable oxygenated tumor cells through methods like chemotherapy or radiation (23). The gene discussed is SLC16A1; the disease is neoplasm.